Magic mushroom compound shows promise for Tough-to-Treat depression and BPD

NCT ID NCT05399498

Completed Symptom relief Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small Phase 2 trial tested a single 25mg dose of psilocybin in 9 adults with both major depressive disorder and borderline personality disorder. Researchers measured changes in depression and BPD symptoms over time. The goal was to see if psilocybin is safe and could help ease symptoms in this complex group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin (a psychedelic compound)
What this could lead to: If it works, this could point toward a new treatment option for people with both depression and borderline personality disorder.
What could go wrong: This is a very small, early-stage trial with only 9 participants, so results may not apply to everyone. Psychedelic therapy can cause intense emotional experiences and is not without risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORDERLINE PERSONALITY DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

borderline personality disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BORDERLINE PERSONALITY DISORDER MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

University of Chicago

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.